Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat

Clinical and Experimental Hypertension

Volumn 28, Issue 5, 2006, Pages 475-488

  Loch, David ^a   Hoey, Andrew ^b   Brown, Lindsay ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

DOCA salt rat; Fibrosis; Hypertension; Hypertrophy; Omapatrilat

Indexed keywords

BRADYKININ; DEOXYCORTICOSTERONE ACETATE; DRINKING WATER; NATRIURETIC FACTOR; OMAPATRILAT; SODIUM CHLORIDE; VASOPEPTIDASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE FIBROSIS; HEART SURGERY; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; MUSCLE ACTION POTENTIAL; MYOCARDITIS; NONHUMAN; PATHOGENESIS; RAT; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNINEPHRECTOMY;

ACTION POTENTIALS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BLOOD PRESSURE; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBROSIS; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY; INFLAMMATION; MALE; MEMBRANE POTENTIALS; METALLOENDOPEPTIDASES; MYOCARDIAL CONTRACTION; PAPILLARY MUSCLES; PYRIDINES; RATS; RATS, WISTAR; SODIUM CHLORIDE, DIETARY; THIAZEPINES; VENTRICULAR REMODELING;

EID: 33745845527     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960600798754     Document Type: Article

References (41)

1. Weber MA. Vasopeptidase inhibitors. Lancet 2001; 358:1525-1532.
2. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356:615-620.
3. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106:920-926.
4. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103-111.
5. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 11:363-372.
6. Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991; 17:456-465.
7. Pham I, Gonzalez W, el Amrani AI, Fournie Zaluski MC, Philippe M, Laboulandine I, Roques BP, Michel JB. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993; 265:1339-1347.
8. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 1997; 43:329-332.
9. Elmarakby AA, Morsing P, Pollock JS, Pollock DM. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats. Vascul Pharmacol 2003; 40:253-259.
10. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998; 39:89-105.
11. Sugimoto T, Ishii M, Hirata Y, Matsuoka H, Miyata A, Toshimori T, Masuda H, Kangawa K, Matsuo H. Increased release of atrial natriuretic polypeptides in rats with DOCA-salt hypertension. Life Sci 1986; 38:1351-1358.
12. A receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003; 42:811-817.
13. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodelling. Hypertension 2003; 42:49-55.
14. A-NADPH oxidase pathway in low-renin hypertension. Circulation 2003; 107:1053-1058.
15. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 1999; 10(suppl 11):S143-S148.
16. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001; 133:687-694.
17. Fenning A, Harrison G, Rose'meyer R, Hoey A, Brown L. L-arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 289:H1408-H1416.
18. Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta 1967; 18:267-273.
19. Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, Dejneka T, Slusarchyk WA, Chao S, Stratton L, Misra RN, Bednarz MS, Asaad MM, Cheung HS, Abboa-Offei BE, Smith PL, Mathers PD, Fox M, Schaeffer TR, Seymour AA, Trippodo NC. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997; 40:1570-1577.
20. Pu Q, Amiri F, Gannon P, Schiffrin EL. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 2005; 23:401-409.
21. Pu Q, Touyz RM, Schiffrin EL. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2002; 20:899-907.
22. Itoh H, Nakao K, Mukoyama M, Yamada T, Hosoda K, Shirakami G, Morii N, Sugawara A, Saito Y, Shiono S, Arai H, Yoshida I, Imura H. Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats. J Clin Invest 1989; 84:145-154.
23. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300.
24. Allcock GH, Venema RC, Pollock DM. The A in ETA should be an upper-case subscript, receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats. Am J Physiol 1998; 275:R245-252.
25. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000; 35:19-24.
26. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101:812-818.
27. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990; 86:1690-1697.
28. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25:227-234.
29. Maki T, Horio T, Yoshihara F, Suga S, Takeo S, Matsuo H, Kangawa K. Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts. Br J Pharmacol 2000; 131:1204-1210.
30. Redondo J, Bishop JE, Wilkins MR. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol 1998; 124:1455-1462.
31. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 1997; 94:14730-14735.
32. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA, Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 2001; 107:975-984.
33. Gallagher AM, Yu H, Printz MP. Bradykinin-induced reductions in collagen gene expression involve prostacyclin. Hypertension 1998; 32:84-88.
34. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Effects of adrenomedullin on cultured rat cardiac myocytes and fibroblasts. Eur J Pharmacol 1999; 382:1-9.
35. Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 1998; 31:505-510.
36. Tomaselli GF, Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999; 42:270-283.
37. Coulombe A, Momtaz A, Richer P, Swynghedauw B, Coraboeuf E. Reduction of calcium-independent transient outward potassium current density in DOCA salt hypertrophied rat ventricular myocytes. Pflugers Arch 1994; 427:47-55.
38. Rials SJ, Wu Y, Xu X, Filart RA, Marinchak RA, Kowey PR. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation 1997; 96:1330-1336.
39. d'Uscio LV, Quaschning T, Burnett JC, Lüscher TF. Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition. Hypertension 2001; 37:28-33.
40. Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 2000; 35:1221-1225.
41. Quaschning T, d'Uscio LV, Shaw S, Lüscher TF. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension 2001; 37:1108-1113.